



NDA 22-427

NDA APPROVAL

Allergan, Inc.
Attention: Paul Stone, Ph.D.
Director, Global Regulatory Affairs
2525 Dupont Drive
Irvine, CA 92612

Dear Dr. Stone:

Please refer to your new drug application (NDA) dated September 28, 2008, received September 30, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act, for Acuvail (ketorolac tromethamine ophthalmic solution) 0.45%.

We acknowledge receipt of your submissions dated September 28, November 3, 10, and 21, 2008, and January 29, March 10, April 23, and 30, June 17 and July 8, 15, and 17, 2009.

This new drug application provides for the use of Acuvail (ketorolac tromethamine ophthalmic solution) 0.45% for the treatment of pain and inflammation following cataract surgery.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert submitted July 17, 2009). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "**SPL for approved NDA 22-427.**"

Submit final printed label carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 22-427.**" Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. We are waiving the pediatric study requirement for this application because the necessary studies are impossible or highly impractical due to limited number of pediatric patients with cataracts.

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090308.htm>

Please submit one market package of the drug product when it is available.

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Raphael R. Rodriguez, Regulatory Project Manager, at (301) 796-0798.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
Acting Director
Division of Anti-Infective and
Ophthalmology Products
Office of Antimicrobial Products
Office of New Drugs
Center for Drug Evaluation and Research

Enclosure: Package insert, Carton labels, Container labels.

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Wiley Chambers
7/22/2009 11:52:14 AM